作者
Noa Kremer, Igor Snast, Efrat Solomon Cohen, Emmilia Hodak, Daniel Mimouni, Moshe Lapidoth, Sigal Mazor, Assi Levi
发表日期
2019/4/1
来源
American Journal of Clinical Dermatology
卷号
20
页码范围
209-216
出版商
Springer International Publishing
简介
Background
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; however, they may cause significant adverse effects and treatment failures, so additional therapeutic modalities with better safety profiles are required. Rituximab and omalizumab are novel biologic agents administered in recent years for the treatment of BP, yet data regarding their use in the disease are limited.
Objective
Our objective was to systematically review the current literature regarding the use of rituximab and omalizumab for the treatment of BP to evaluate their safety and efficacy.
Methods
A systematic review of all publications evaluating patients with BP treated with rituximab or omalizumab was performed. The primary outcome was clinical …
学术搜索中的文章
N Kremer, I Snast, ES Cohen, E Hodak, D Mimouni… - American Journal of Clinical Dermatology, 2019